In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims ...
Eucalyptus brings >775,000 customers, multi-country operating presence, >20 peer-reviewed studies on outcomes/adherence/safety, and Australian Council on Healthcare Standards accreditation. Tim Doyle ...
Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.
FDA Will Drop Two-Study Requirement for New Drug Approvals, Aiming to Speed Access U.S News February 18, 2026 ...
On the heels of a Type A meeting with FDA’s Center for Biologics and Research (CBER), Moderna’s seasonal influenza vaccine ...
The broader Miami-Fort Lauderdale-West Palm Beach metro produced $533.7 billion in GDP in 2023, a nearly 9% year-over-year ...
Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively. Learn how data-driven insights and affordability ...
Crohn’s patients taking Omvoh saw three-years of remission when taking Omvoh, according to new long-term data released by Eli Lilly. 1 The data is the result of the Phase 3 VIVID-2 open label ...
ACIP vice chair has even publicly accused FDA Commissioner Marty Makary of blocking or stalling efforts to pull the vaccines off the market. According to reports from that time period, ACIP members ...
What’s been overlooked is that the FDA already has the power to fix this. Without new legislation, pilot programs, or years ...
In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary ...
Scaling without losing local relevance requires humility, trust, and a willingness to relinquish the illusion that control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results